Suprefort
Pancreas Extract Bioregulator · Pancreatic Cytomax · Супрефорт
Suprefort is the Cytomax pancreas complex. Pancragen (Lys-Glu-Asp-Trp, KEDW) is the synthetic islet-adjacent tetrapeptide. Neither is insulin, tirzepatide, or a beta-cell transplant.
Use-case scores
0–10 against the evidence we have, not a gym ranking. Hidden domains do not apply here.
- Longevity / aging3.5/10
Khavinson-school tissue peptide. Single-lab concentration after haircut. Not a Western Phase 3 geroprotector.
- Metabolic / weight3/10
GI/metabolic organ map. Not a GLP-1 and not a diabetes drug.
Compound card
- Sequence
- Pancreas peptide complex (mixture, not a single CAS)
- Class
- Khavinson Cytomax capsule complex (Pancreas)
- Formula
- Polypeptide extract (Pancreatic tissue <10 kDa)
- Status
- Not FDA-approved · research use
How it works
Suprefort (A-1) is a Cytomax natural polypeptide extract from the pancreas of young calves - the first numbered entry in the entire Khavinson A-Series, reflecting its foundational metabolic importance. The pancreas performs two critical functions: exocrine (secreting digestive enzymes into the small intestine) and endocrine (secreting insulin, glucagon, and somatostatin via the islets of Langerhans). Age-related pancreatic decline manifests on both fronts: progressive loss of exocrine acinar cell function reduces digestive enzyme output (contributing to malabsorption and bloating after age 50), while beta-cell insufficiency reduces insulin secretion capacity and/or insulin sensitivity - the upstream driver of type 2 diabetes.
Suprefort delivers short peptide signals (<10 kDa) from bovine pancreatic tissue. These peptides enter pancreatic cell nuclei to reactivate age-silenced transcription factors governing: insulin gene expression (PDX-1, NeuroD1 - the master regulators of beta-cell identity), digestive enzyme synthesis (amylase, lipase, trypsinogen), and islet cell proliferation capacity. Critically, Suprefort does not provide exogenous insulin or lower blood glucose directly - it works at the gene regulation level to restore the pancreas's own capacity to mount an appropriate insulin and enzyme response.
In Khavinson's clinical data, courses of pancreatic bioregulators were associated with improved post-prandial glucose control and reduced fasting glucose variability. The standard pairing is Suprefort (A-1, pancreas) + Svetinorm (A-7, liver) for comprehensive metabolic axis support, since hepatic insulin sensitivity and glucose output are tightly coupled to pancreatic insulin secretion.
Source: PMID: 15677927
Khavinson map
Canonical 41Used in bioregulator stacks
Manufacturer-style organ combinations - not FDA protocols. Every name is a live leaf.
The Khavinson school
Vladimir Khatskelevich Khavinson (1946–2024) spent five decades at what became the St. Petersburg Institute of Bioregulation and Gerontology arguing a simple, stubborn idea: aging is, in part, a failure of tissue-specific peptide signals, and those signals can be restored. The first products were not “peptides” in the Instagram sense. They were Cytamins - polypeptide fractions isolated from a named organ of young animals. Later commercial refinements of those fractions are sold as Cytomaxes (Cytomed / NPCRIZ): still mixtures, still oral capsules, still defined by the source organ rather than a single sequence. When the group identified short active motifs inside those mixtures, they synthesized them as Cytogens - di-, tri-, and tetrapeptides with a one-letter code (KE, AEDG, KED, EDR, KEDP, and so on).
That three-layer stack is the whole map. Cytamin / pharmaceutical extracts (Thymalin, Epithalamin, Cortexin, Retinalamin, Prostatilen) are the clinic-era injectables registered in the former Soviet pharmacopeia. Cytomaxes are the capsule complexes Cytomed still lists as a 21-SKU organ line. Cytogens are the defined synthetics. English-language educators, including Brenden Henry’s public writing at Peptide Science Institute, add a further commercial distinction - later analog SKUs (N-acetyl, amidate, “V2” complexes) sold as more stable or more diverse than the original Cytomed lots. That last layer is a product taxonomy, not a Khavinson paper. We describe it so readers are not gaslit by three bottles with the same organ name. We do not reproduce paid Peptide Mastery protocols, Precision Cell Method language, or anyone else’s course IP.
Full Cytamin → Cytomax → Cytogen map, literature limits, and how we counted 41
The mechanism Khavinson published is epigenetic, not receptor-agonist in the GLP-1 sense. Short peptides are claimed to enter nuclei, interact with DNA/histones, and reopen tissue-specific transcription that condensed with age (heterochromatin → euchromatin). Reviews in the Bulletin of Experimental Biology and Medicine and Neuroendocrinology Letters (PMID 14523363, 15677927, 23888677) are the citable core. Complementary GI pharmacology is not mystical: di- and tripeptides are PEPT1/LAT substrates, which is why oral capsules are even a conversation. What is not established in Western Phase 3 programs is organ-by-organ disease treatment, telomere reversal as a clinical endpoint, or the manufacturer claim that Cytomax is “a third stronger” than Cytogen. Those are NPCRIZ marketing sentences.
Khavinson’s group published hundreds of papers, many in Russian, many in the same journal family. That is a real literature. It is also a literature with limited independent Western replication, small n, and a habit of using one review PMID as a stamp on every organ. On this site a leaf earns its organ story, its Cytomax↔Cytogen pair, its sequence if it has one, and an honest sentence about what has not been shown. Reconstitution math belongs on cytogens sold as vials. Cytomax capsules do not get a fake 5 mg vial.
The 41 we treat as canonical are the 21 Cytomaxes on the public e-peptide/Cytomed list, the 12 Cytogens on that same commercial line (including Vesilut, which Western catalogs often drop), plus eight historically load-bearing molecules that sit beside the capsule SKUs: Epitalon, Vilon, Thymogen, Livagen, Cortagen, Prostamax, Thymalin, and Epithalamin. Honluten, Cortexin, Retinalamin, Prostatilen, Thymulin, N-acetyl-epitalon-amidate, Pinalex, and the GPL Man / GPL Femme kits are covered as adjacent - same school or same storefront, not padded into a fake 41.
Public English-language teaching (including Brenden Henry at peptidescienceinstitute.com) is cited as context, not copied. Paid Peptide Mastery / Peptide Salvation text stays theirs.
History of this molecule
Khavinson’s pancreatic papers on Pancragen are among the more molecule-specific in the cytogen set - insulin transcription, islet cell aging. Suprefort is the complex that sits on the Cytomax shelf for the same gland. Metabolic YouTube will try to sell this as an oral Ozempic. It is not a GLP-1 receptor agonist.
Diabetes remains metformin/GLP-1/insulin territory. A 10-day capsule course is not A1c policy.
Caveats
Pancreas Cytomax is not a US dietary-supplement monograph and not a drug. The tissue-extract model means lot-to-lot composition is a fingerprint, not a single CAS number. English-language “V2” bottles that claim more peptide diversity are a later commercial layer (mass-spec marketing from specific brands) - they are not Khavinson’s 1990s papers. Animal-source capsules are inappropriate if the reader has a religious or allergy constraint on the source species. None of this replaces care for the actual organ disease. Hypoglycemia on insulin plus an uncharacterized islet peptide is not a vibe.
Full 41-map: Khavinson bioregulators index · Bioregulator stacks
Research Use Cases
- ✓Pancreatic Cytomax vs Pancragen
- ✓Not digestive-enzyme replacement or metabolic regulation
Dosing
| Phase | Dose | Frequency | Notes |
|---|---|---|---|
| Mini-Course / General Preventive (1 box) | 2 capsules (20 mg) | Once daily for 10 days, 30 min before meals | Standard Khavinson mini-course (20 caps). Repeat every 6 months. Most effective when taken before the largest meal of the day. Pair with Svetinorm (A-7) for the complete metabolic axis protocol. |
| Full Monthly Course (Metabolic Health) | 2 capsules (20 mg) | Twice daily for 30 days (120 caps = 2× 60-cap boxes) | Bi-annual 30-day courses for pre-diabetic adults, metabolic syndrome, or declining digestive enzyme output. Core metabolic stack: Suprefort (A-1) + Svetinorm (A-7, liver) + Ventfort (A-3, blood vessels) for full metabolic-vascular health. |
| Intensive / Pancreatic Support Protocol | 2 capsules (20 mg) | Twice daily, repeated monthly | For established metabolic dysfunction, significant digestive enzyme insufficiency, or post-pancreatitis recovery. Physician supervision mandatory for any diabetic patient. Not a replacement for insulin therapy. Max: 4 caps/day (40 mg). |
Administration
Suprefort: Not a research vial vs Oral capsule
- The defined-sequence vial in this aisle is the cytogen pair (Pancragen (KEDW)), a different SKU.
- There is no pharmaceutical-extract SKU that is this capsule in a syringe.
- Reconstitute Pancragen if you bought KEDW. A Suprefort cake is a mis-ID. Do not stack casually with tirzepatide without a clinician.
- Suprefort is an oral capsule complex. It is not a 5 mg lyophilized research vial.
- Inventing recon math for a zero-mg Cytomax vial is how people inject the wrong product.
- Not an official Cytomed sublingual tablet, IM ampoule, or eye drop either.
- Official form for Suprefort: swallow the capsule with water. No reconstitution step and no 5 mg cake.
- Pancreas Cytomax (Cytomed A-1). Not insulin, not a GLP-1 agonist, not an oral Ozempic. Metabolic YouTube will try anyway.
- Course-based (10–30 days, a few times a year in manufacturer folklore), not a daily forever drug.
- Pancreas Cytomax is a peptide mixture / lot fingerprint, not a single CAS. English “V2” bottles are a later commercial layer, not a Khavinson RCT.
- Russian school literature is not an FDA organ-disease label.
- Third-party lingual SKUs exist in the wild. We do not claim sublingual as the official Cytomed Cytomax form.
Timeline
Who it is for
Metabolic Syndrome / Pre-Diabetes (Ages 45+)
LowRestores pancreatic beta-cell gene expression for insulin synthesis and secretory capacity. For preventive metabolic management, not acute glycemic control.
Digestive Enzyme Insufficiency
LowAlso targets exocrine acinar cells restoring amylase, lipase, and protease production - addressing the often-overlooked digestive aspect of pancreatic aging.
Safety & Considerations
Natural glandular extract (Cytomax) from bovine pancreatic tissue, <10 kDa. Contains no insulin or active hormones. Not a diabetes medication. Meets European/Russian veterinary standards. Physician oversight required for diabetic patients.
Regulatory & Legal Status
Not currently on the WADA 2026 Prohibited List. Policies may change - verify before competition.
Research Chemical
US Compounding: Not eligible / not available
⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.
Limits of current evidence
- Cytomax SKUs are oral capsules. Do not run SubQ reconstitution math on a zero-mg vial.
- Lot-to-lot composition is a fingerprint, not one sequence.
- This site will not treat the named organ disease from a peptide page.
- English-language V2 / analog bottles are a later commercial layer, not a Khavinson RCT.
Verdict
Suprefort is a Cytomax capsule complex from Pancreas. It is not the paired cytogen, not a 5 mg research cake, and not a US supplement monograph. The organ story is in the dossier on this page.
Interactions & Contraindications
Monitor glucose if already diabetic. Not a substitute for indicated therapy.
Synergies & Common Stacks
Complex vs cytogen. Neither replaces indicated diabetes care.
Appears in goal guides
Goal guides are maps, not clinic protocols. A mention here is not a treatment plan.
Frequently Asked Questions
Oral capsule or injection?▼
Suprefort vs Pancragen?▼
Will this replace insulin?▼
GLP-1 overlap?▼
Reconstitution?▼
Can Suprefort help with blood sugar?▼
Why is Suprefort A-1 - the very first in the series?▼
References
- Khavinson VKh et al. “Pancragen effects on insulin-producing cells (Khavinson pancreas series).” Bulletin of Experimental Biology and Medicine (2012). PMID: 22380579
- Khavinson VKh et al. “Tissue-specific effects of peptides.” Bulletin of Experimental Biology and Medicine (2005). PMID: 15677927
- Khavinson VKh, Lin’kova NS, Tarnovskaya SI “Short peptides regulate gene expression.” Bulletin of Experimental Biology and Medicine (2013). PMID: 23888677
- Khavinson VKh, Morozov VG “Peptide regulation of aging: from experimental studies to clinical practice.” Advances in Gerontology (2003). PMID: 14523363
- Khavinson VKh “"Peptide bioregulators - a new class of geroprotectors".” Bulletin of Experimental Biology and Medicine (2002). PMID: 12677266
📚 Related Articles
Get Suprefort from Vita-Stream - a distributor for Khavinson-line oral capsules. No reconstitution math on a Cytomax bottle.
Affiliate link · Full review